Bank Of New York Mellon Corp Harmony Biosciences Holdings, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$30.8 - $53.92 $8.03 Million - $14 Million	260,570 New	260,570 $8.51 Billion
Q4 2022 Feb 14, 2023	BUY	$45.4 - $60.91 $12.4 Million - $16.7 Million	273,637 New	273,637 $15.1 Million
Q3 2022 Nov 14, 2022	BUY	$42.06 - $55.45 $1.78 Million - $2.34 Million	42,280 Added 18.62%	269,402 $11.9 Million
Q2 2022 Aug 15, 2022	BUY	$33.54 - $52.15 $329,295 - $512,008	9,818 Added 4.52%	227,122 $11.1 Million
Q1 2022 May 11, 2022	BUY	$33.14 - $51.13 $592,974 - $914,869	17,893 Added 8.97%	217,304 $10.6 Million
Q4 2021 Feb 11, 2022	BUY	$34.09 - $43.91 $4.46 Million - $5.75 Million	130,858 Added 190.89%	199,411 $8.5 Million
Q3 2021 Nov 12, 2021	BUY	$25.68 - $38.61 $601,091 - $903,744	23,407 Added 51.85%	68,553 $2.63 Million
Q2 2021 Aug 11, 2021	BUY	$25.96 - $33.44 $832,511 - $1.07 Million	32,069 Added 245.23%	45,146 $1.27 Million
Q1 2021 May 13, 2021	BUY	$27.56 - $40.37 $49,029 - $71,818	1,779 Added 15.75%	13,077 $432,000
Q4 2020 Feb 09, 2021	BUY	$31.74 - $51.34 $358,598 - $580,039	11,298 New	11,298 $408,000

246

45.5M

108K

49.2K

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.29B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.